Premium
SHORT COMMUNICATION: EFFECTS OF VASOACTIVE INTESTINAL POLYPEPTIDE INFUSIONS ON RENAL FUNCTION IN PATIENTS WITH LIVER DISEASE
Author(s) -
Calam J.,
Unwin R. J.,
Dorudi S.,
Taylor C.,
Springer C. J.,
Peart W. S.
Publication year - 1988
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1988.tb01105.x
Subject(s) - vasoactive intestinal peptide , medicine , endocrinology , renal function , plasma renin activity , cirrhosis , reabsorption , renal physiology , liver disease , kidney , renal sodium reabsorption , renin–angiotensin system , chemistry , neuropeptide , blood pressure , receptor
SUMMARY 1. The effect of intravenous vasoactive intestinal peptide (VIP, 6 pmol/kg per min) on renal function in six patients with cirrhosis of the liver was examined. 2. VIP caused generalized vasodilation and increased plasma renin activity, but diminished the glomerular filtration rate by about one third. 3. The excretion of water, sodium, potassium and calcium also fell significantly. 4. These results differ from our findings in normal man in whom VIP diminished water and electrolyte secretion largely by increasing tubular reabsorption. 5. It is concluded that the elevated VIP levels present in patients with severe liver disease may affect renal function, but that the presence of liver disease may affect renal responses to VIP.